(2003; 40 pages)
Annex B - The anatomy of a patent
When somebody applies for a patent they have to explain in their patent document why their invention is "clever" enough to deserve a patent.
According to the theory of the patent bargain, a patent document has to explain how to carry out the invention, so it needs to contain "How To" instructions. Since the monopoly rights give exclusive control over the invention to the patent holder, the document must also carefully define what the invention is. These integral parts of a patent are called the "description" and the "claims" respectively. A "title page" typically provides administrative and procedural details of the patent including such things as the number of the patent and of the application, the date of priority, the date of filing of the application, the date of publication of the application, the date of grant of the patent, the title of the invention, the name of the applicant and of the inventor. Drawings typically accompany the description. A brief summary of the invention, the "abstract" is often also available, although not strictly part of the patent application. By way of illustration of these concepts, we have reproduced a patent document (starting on the next page). This is a granted European patent (number 0273277) that protects the antiretroviral drug stavudine. Stavudine (also known as d4T) is an important nucleoside reverse transcriptase inhibitor used in antiretroviral combination therapy. Bristol-Myers Squibb (BMS) sells it under the trade name Zerit®. This patent document is conveniently and unusually short.
The title pages (pages 1-2) contain a lot of information, including the following. The title of the invention is in this case "Pharmaceutical composition comprising 3'-deoxythymidin-2'-ene (3'-deoxy-2',3'- didehyrdothymidine) in treating patients infected with retrovirus [sic]". Although this will not be self-evident to most nonpharmacists, this is stavudine. The owner (proprietor) of the patent is listed as Yale University. The inventors are named as Tai-Shun Lin and William H. Prusoff who worked at Yale University. This European patent claimed priority from an earlier patent application. The concept of priority and the priority year and why these are so important for the international patent system is outlined in section 3.1. In this case, priority is claimed from American patent application 942666, which was filed on December 17th 1986. This European patent was filed on the December 11th 1987, less than a year later as required to claim priority. The "references cited" entry on the title pages provides a list of the documents that the European Patent Office knew about when they granted this patent. This concept of the "state of the art" is also discussed in section 3.2.
Following the title pages comes the "description" (pages 3-7). The description opens by "setting the scene" for the invention. In this case the invention relates to "pharmaceutical compositions comprising 3'- deoxythymidin-2'-ene (3'-deoxy-2',3'- didehyrdothymidine for treating warm blooded animals infected with retroviruses". For the avoidance of doubt, "warm blooded animals" includes humans in this context. Crucially, on line 47 of page 34, the inventors tell the reader that "[t]he compound 3'-deoxythymidin-2'-ene is known per se from Carbohydrate Research, Vol. 73, 1979, pages 113 to 124 (Elsevier Scientific Publishing Company, Amsterdam, NL)" and they go on to say "However, no therapeutical use of this compound is described in this document". This means that the invention in this European patent is not the making of a new chemical entity. This invention is the fact that the inventors have discovered that this compound, the structure of which was already known back in 1979, has a medical use. The "finding of potent antiretroviral activity" is said to be unexpected. We discuss this on p. 13.
Pages 4 to 7 of the description outline methods for making and testing the compound. As one of the main purposes of patents is to make technical information available to the public, this disclosure should happen "in a manner sufficiently clear and complete for the invention to be carried out by a person skilled in the art".
On page 7, the claims appear. These define the scope of the patent protection. As outlined above, the inventors have discovered that this compound has a medical use in combating retroviruses, so that is what they claim as their "intellectual property". Claim 1 forbids anybody but the patent owner (Yale University) or anybody they give permission to (e.g. BMS) to make a "pharmaceutical composition for treating warm blooded animals infected with a retrovirus, comprising as an active ingredient an anti-retroviral effective amount of 3'- deoxythymidin-2'-ene, either alone or in admixture with usual additives such as solid, liquid or liquefied gaseous diluents". If you do it without their permission, in a country where this patent is in effect, you will be infringing their patent and they will be able to sue you. Claims 2-7 define the scope of subsidiary patent protection. For example, if you make a pharmaceutical composition as claim 1 defines but it is specifically to treat HIV, then you will infringe not only claim 1 but claim 3 as well.
As we have explained above, the TRIPS Agreement does not require WTO Members to grant patents for this sort of invention. Notwithstanding this, if you look at the patent table, you will see that South Africa did grant a patent for this invention.
 TRIPS Article 29.1.
 Claim 8 is a so-called "Swiss claim", for which see Correa, C.M. " Integrating Public Health Concerns into Patent Legislation in Developing Countries", South Centre, 2nd edition, Geneva, September 2001.
 Patent holders have choices in how they exploit their patents. In 2001, MSF South Africa asked Yale, the owner of a key patent on Zerit, to authorise imports to South Africa of generic versions of stavudine for use in providing treatment free of charge to people with HIV/AIDS unable to afford it. A generic manufacturer had offered to produce it 34 times cheaper than BMS. Other NGOs, Yale University students, technicians and researchers joined forces in a petition to support MSF's request. BMS bowed to the pressure and announced that they would allow generic competition, as well as massively reduce the price of the patented drug. For more details on the case, see for example "The high cost of living - Yale shares profits from AIDS drugs" in Le Monde Diplomatique, February 2002 (http://mondediplo.com/2002/02/04stavudine). For context and further details see the Consumer Project on Technology page on stavudine (http://www.cptech.org/ip/health/d4T.html).
(12) EUROPEAN PATENT SPECIFICATION
(45) Date of publication of patent specification: 24.06.92 Int. (51) A61K 31/70
(21) Application number: 87118407.3
(22) Date of filing: 11.12.87
(54) Pharmaceutical composition comprising 3'-deoxythymidin-2'-ene (3'-deoxy-2',3'-didehydrothymidine) in treating patients infected with retrovirus.
(30) Priority: 17.12.86 US 942666
(43) Date of publication of application:
(45) Publication of the grant of the patent:
(84) Designated Contracting States:
(56) References cited:
BIOCHEM. BIOPHYS. RES. COMMUN., vol. 142, no. 1, January 15, 1987, pages 128 - 134, Academic Press, Inc.; M. Baba et al.: " Both 2' 3'-dideoxythymidine and its 2', 3'-unsaturated derivative (2',3'- dideoxythymidinene are potent and selective inhibitors of human immunodeficiency virus replication in vitro"
(73) Proprietor: YALE UNIVERSITY
(72) Inventor: Lin, Tai-Shun
(74) Representative: Reitzner, Bruno, Dr.
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).
Rank Xerox (UK) Business Services
EP 0 273 277 B1
MOL. PHARMACOL, vol. 32, no. 1, July 1987, pages 162-167, The American Society for Pharmacology and Experimental Therapeutics; J. BALZARINI et al.: "The anti-HTLV-lll(anti-HIV) and cytotoxic activity of 2', 3'-didehydro-2',3'- dideoxyribonucleosides: A comparison with their parental 2', 3'-dideoxyribonucleosides"
CANCER LETTERS, vol. 8, 1980, pages 307-315, Elsevier, North- Holland Scientific Publishers Ltd., NL; P. Furmanski et al.: "Inhibtlon by 2',3'-dldeoxythymidlne of retro-viral infection of mouse and human cells"
BIOCHEM. BIOPHYS. RES. COMMUN., vol. 140, no. 2, October 30, 1986, pages 735-742, Academic Press Inc.; J. BALZARINI et al.: "Potent and selective anti-HTLV-lll/LAV activity of 2',3'-dideoxycytidinene the 2', 3'-unsaturated derivative of 2', 3'-dideoxycytidine"
PROC. NATL. ACAD. SCI. USA, vol. 83, March 1986, pages 1911-1915, H. MITSUYA et al.: "Inhibition of the in vitro infectivity and cytophathic effect of human T-lymphotropic virus type Ill/lymphadenopathy-associated virus (HTLV-III/LAV) by 2", 3'-dideoxy-nucleosides"
CARBOHYDRATE RESEARCH, vol. 73, 1979, pages 113-124, Elsevier Scientific Publishing Company, Amsterdam, NL; T. ADACHI et al.: "Synthesis of uracil and thymine nucleosides of unsaturated 5-(aminoacyl)amino-pentofuranoses".
The present invention relates to pharmaceutical compositions comprising 3'-deoxythymidin-2'-ene (3'-deoxy-2',3'-didehydrothymidine) for treating warm blooded animals infected with retroviruses.
Acquired immunodeficiency syndrome (AIDS) is generally accepted to be a consequence of infection with the retrovirus variously termed human T-lymphotropic virus type III (HTLV-III), lymphadenopathy-associated virus (LAV), AIDS associated retrovirus (ARV), or human immunodeficiency virus (HIV). A number of compounds have demonstrated antiviral activity against this virus which include HPA-23 (D. Dormont, B. Spire, F. Barre-Sinoussi, L. Montagnier and J. C. Chermann, Ann. Inst. Pasteur/Virol., 75, 136E, (1985) and W. Rosenbaum, D. Dormont, B. Spire, E. Vilmer, M. Gentilini, C. Griscelli, L. Montagnier, F. Barre-Sinoussi and J. C. Chermann, Lancet i, 450, (1985)), interferons (D. D. Ho. K. L. Hartshorn, T. R. Rota, C. A. Andrews, J. C. Kaplan, R. T. Schoolkey and M. S. Hirsch, Lancet i, 602, (1985)), ribavirin (J. B. McCormick, J. P. Getchell, S. W. Mitchell and D. R. Hicks, Lancet ii, 1367, (1984)), phosphonoformate (E. G. Sandstrom, J. C. Kaplan, R. E. Byington and M. S. Hirsch, Lancet, i, 1480, (1984) and P. S. Sarin, Y. Taguchi, D. Sun, A. Thornton, R. C. Gallo and B. Oberg, Biochem. Pharmac., 34, 4075, (1985)), ansamycin, (R. Anand, J. L. Moore, A. Srinivason, V. Kalyanaraman, D. Francis, P. Feorino and J. Curran, Abstracts of the International Conference on Acquired Immune Deficiency Syndrome (AIDS), April 14-17, Atlanta, GA, page 72, (1985)), suramin (H. Mitsuya, M. Popovic, R. Yarchoan, S. Matsushita, R. C. Gallo and S. Broder, Science, 226, 172, (1984); H. Mitsuya, S. Matsushita, M. E. Harper and S. Broder, Cancer Res., 45, 4583s, (1985) and E. DeClercq, Cancer Lett., 8, 9, (1979)), imuthiol (A. Pompidou, D. Zagury, R. C. Gallo, D. Sun. A. Thornton and P. S. Sarin, Lancet, ii, 1423, (1985)), penicillamine (P. Chandra and P. S. Sarin, Drug Res., 36, 184, (1986)), rifabutin (R. Anand, J. Moore, P. Feorino, J. Curran and A. Srinivasan, Lancet, i, 97, (1986)-), AL-721 (P. S. Sarin, R. C. Gallo, D. I. Scheer, F. Crews and A. S. Lippa, New Engl. J. Med., 313, 1289, (1985)), 3'-azido-3'-deoxythymidine (W. Ostertag. T. Cole, T. Crazier, G. Gaedicke, J. Kind, N. Kluge, J. C. Krieg. G. Roselser, G. Sheinheider, B. J. Weimann and S. K. Dube, Proceedings of the 4th International Symposium of the Princess Takamatsu Cancer Research Fund, Tokyo, 1973, Differentiation and Control of Malignancy of Tumor Cells, Eds. W. Nakahara, T. Ono, T. Sugimura and H. Sugano, page 485, University of Tokyo Press, Tokyo, (1974); W. Ostertag, G. Roseler, C. J. Kreig, T. Cole, T. Crozier, G. Gaedicke, G. Steinheider, N. Kluge and S. K. Dube, Proc. Natn. Acad. Sci. USA, 71, 4980, (1974); S. L. Dube, G. Gaedicke, N. Kluge, B. J. Weimann, H. Melderis, G. Steinheider. T. Crozier, H. Beckmann and W. Ostertag, Proceedings of the 4th International Symposium of the Princess Takamatsu Cancer Research Fund, Tokyo, 1973, Differentiation and Control of Malignancy of Tumor Cells, Eds. W. Nakahara. T. Ono, T. Sugimura and H. Sugano, page 99, University of Tokyo Press, Tokyo, (1974); S. K. Dube, I. B. Pragnell, H. Kluge, G. Gaedicke, G. Steinheider and W. Ostertag, Proc. Natn. Acad. Sci. USA, 72, 1863, (1975) and H. Mitsuya, K. J. Weinhold, P. A. Furman, M. H. St. Clair, S. Lehrman Nusinoff, R. C. Gallo, D. Bolognesi, D. W. Barry and S. Broder, Proc. Natn. Acad. Sci. USA, 82, 7096, (1985)), and more recently various 2',3'-dideox-ynucleosides (H. Mitsuya and S. Broder, Proc. Natn. Acad. Sci. USA, 83, 1911, (1986)), of which 2',3'-dideoxycytidine (ddCyd) is the most potent. A review of these and other compounds evaluated for their activities against HIV, as well as a discussion of the AIDS problem in general, has been presented (E. DeClercq, J. Med. Chem., 29, 1561, (1986)).
Applicants previously found 2',3'-dideoxycytidin-2'-ene (2',3'-dideoxy-2',3'-didehydrocytidine; D4C) a derivative of 2',3'-dideoxycytidine (ddCyd) to have antiviral activity against HIV (Lin et al, Biochem. Pharmacol, in press). This provided the stimulus to synthesis 3'-deoxythymidin-2'-ene (3'-deoxy-2',3'-didehydrothymidine) even though Mitsuya and Broder, supra found 2',3'-dideoxythymidine (3'-deox-ythymidine) to be a very poor inhibitor of HTLV-III/LAV. Applicants' finding of potent antiviral activity with 31-deoxythymidin-2'-ene was, therefore, unexpected based on their report.
The compound 3'-deoxythymidin-2'-ene is known per se from Carbohydrate Research, Vol. 73, 1979, pages 113 to 124 (Elsevier Scientific Publishing Company, Amsterdam, NL). However, no therapeutical use of this compound is described in this document.
The antiretroviral activity of the saturated compounds 2'3'-dideoxythymidine and cytidine is known from Biochem.Biophys. Res.Commun., Vol. 140, No. 2, October 30, 1986, esp. page 736. This document also discloses the activity of the unsaturated derivative 2'3'-dideoxycytidinene.
The present invention is directed to a pharmaceutical composition for treating warm blooded animals infected with a retrovirus, comprising as an active ingredient an anti-retroviral effective amount of 3'-deoxythymidin-2'-ene, either alone or in admixture with usual additives such as a solid, liquid or liquefied gaseous diluents.
Preferred embodiments are recited in the dependent claims. The structure of 3'-deoxythymidin-2'-ene (3'-deoxy-2',3'-didehydrothymidine; D4T) is as follows:
3'-Deoxythymidin-2'-ene (3'-deoxy-2',3'-didehydrothymidine) has antiviral activity against retroviruses, e.g., murine leukemia virus and human immunodeficiency virus, i.e., HIV; HTLV III/LAV virus (the AIDS virus).
Retroviruses are RNA viruses whose genome contains copies of high-molecular weight single-stranded RNA. The virion contains reverse transcriptase. Non-limiting examples of retroviruses include leukemia and sarcoma viruses of animals, foamy viruses of primates and some slow viruses, e.g., visna and maedi of sheep.
A synthesis for the active compound of the present invention is illustrated in the following reaction scheme:
3'-Deoxythymidin-2'-ene (3'-deoxy-2',3'-didehydrothymidine) (4) can be synthesized basically by the methodology of J. P. Horwitz, J. Chua, M. A. DaRooge, M. Noel and I. L. Klundt, J. Org. Chem., 31, 205, (1966) with minor modifications. With reference to the above reaction scheme, treatment of thymidine (1) with methanesulfonyl chloride in pyridine at 0°C gives the corresponding disulfonate 2. Refluxing compound 2 with 1 N NaOH solution in ethanol produces the 3',5'-cyclic ether 3. Treatment of compound 3 with potassium t-butoxide in dry DMSO yields the desired 2'3'-unsaturated derivative 4.
The pharmaceutical composition according to the invention may be present in the form of a sterile and/or physiologically isotonic aqueous solution or in dosage unit form, e.g. in the form of tablets (including lozenges and granules), caplets, dragees, capsules, pills, ampoules or suppositories.
"Medicament" as used herein means physically discrete coherent portions suitable for medical administration. "Medicament in dosage unit form" as used herein means physically discrete coherent units suitable for medical administration, each containing a daily dose or a multiple (up to four times) or a sub-multiple (down to a fortieth) of a daily dose of the compound of the invention in association with a carrier and/or enclosed within an envelope. Whether the medicament contains a daily dose, or for example, a half, a third or a quarter of a daily dose will depend on whether the medicament is to be administered once or, for example, twice, three times or four times a day, respectively.
The pharmaceutical compositions according to the invention may, for example, take the form of suspensions, solutions and emulsions of the active ingredient in aqueous or non-aqueous diluents, syrups, granulates or powders.
The diluents to be used in pharmaceutical compositions (e.g., granulates) adapted to be formed into tablets, dragees, capsules and pills include the following: (a) fillers and extenders, e.g., starch, sugars, mannitol and silicic acid; (b) binding agents, e.g., carboxymethyl cellulose and other cellulose derivatives, alginates, gelatine and polyvinyl pyrrolidone; (c) moisturizing agents, e.g., glycerol; (d) disintegrating agents, e.g., agaragar, calcium carbonate and sodium bicarbonate; (e) agents for retarding dissolution, e.g., paraffin; (f) resorption accelerators, e.g, quaternary ammonium compounds; (g) surface active agents, e.g., cetyl alcohol, glycerol monostearate; (h) adsorptive carriers, e.g., kaolin and bentonite; (i) lubricants, e.g., talc, calcium and magnesium stearate and solid polyethyl glycols.
The tablets, dragees, capsules, caplets and pills formed from the pharmaceutical compositions of the invention can have the customary coatings, envelopes and protective matrices, which may contain opacifiers. They can be so constituted that they release the active ingredient only or preferably in a particular part of the intestinal tract, possibly over a period of time. The coatings, envelopes and protective matrices may be made, for example, from polymeric substances or waxes.
The active ingredient can also be made up in microencapsulated form together, with one or several of the above-mentioned diluents.
The diluents to be used in pharmaceutical compositions adapted to be formed into suppositories can, for example, be the usual water-soluble diluents, such as polyethylene glycols and fats (e.g., cocoa oil and high esters, [e.g., C14-alcohol with C16-fatty acid]) or mixtures of these diluents.
The pharmaceutical compositions which are solutions and emulsions can, for example, contain the customary diluents (with, of course, the above-mentioned exclusion of solvents having a molecular weight below 200, except in the presence of a surface-active agent), such as solvents, dissolving agents and emulsifiers. Specific non-limiting examples of such diluents are water, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (for example, ground nut oil), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitol or mixtures thereof.
For parenteral administration, solutions and emulsions should be sterile and, if appropriate, bloodisotonic.
The pharmaceutical compositions which are suspensions can contain the usual diluents, such as liquid diluents, e.g., water, ethyl alcohol, propylene glycol, surface-active agents (e.g., ethoxylated isostearyl alcohols, polyoxyethylene sorbite and sorbitane esters) microcrystalline cellulose, aluminium metahydroxide, bentonite, agar-agar and tragacanth or mixtures thereof.
All the pharmaceutical compositions according to the invention can also contain coloring agents and preservatives, as well as perfumes and flavoring additions (e.g., peppermint oil and eucalyptus oil) and sweetening agents (e.g., saccharin and aspartame).
The pharmaceutical compositions according to the invention generally contain from 0.5 to 90% of the active ingredient (3'-deoxythymidin-2'-ene (3'-deoxy-2',3'-didehydrothymidine)} by weight of the total composition.
In addition to 3'-deoxythymidin-2'-ene (3'-deoxy-2'3'-didehydrothymidine), the pharmaceutical compositions and medicaments according to the invention can also contain other pharmaceutically active compounds.
Any diluent in the medicaments of the present invention may be any of those mentioned above in relation to the pharmaceutical compositions of the present invention. Such medicaments may include solvents of molecular weight less than 200 as the sole diluent.
The discrete coherent portions constituting the medicament according to the invention will generally be adapted by virtue of their shape or packaging for medical administration and may be, for example, any of the following: tablets (including lozenges and granulates), pills, dragees, capsules, suppositories and ampoules. Some of these forms may be made up for delayed release of the active ingredient. Some, such as capsules, may include a protective envelope which renders the portions of the medicament physically discrete and coherent.
The preferred daily dose for administration of the medicaments of the invention is 2.5 to 250 mg of active ingredient in the case of intravenous administration and 25 to 250 mg of active ingredient in the case of oral administration.
The production of the above-mentioned pharmaceutical compositions and medicaments is carried out by any method known in the art, for example, by mixing the active ingredient(s) with the diluent(s) to form a pharmaceutical composition (e.g., a granulate) and then forming the composition into the medicament (e.g. tablets).
It is envisaged that the active compound, namely, 3'-deoxythymidin-2'-ene (3'deoxy-2',3'-didehydrothymidine), will be administered perorally, parenterally (for example, intramuscularly, intraperitoneally, subcutaneously or intravenously) rectally or locally, preferably orally or parenterally, especially perlingually or intravenously. Preferred pharmaceutical compositions and medicaments are, therefore, those adapted for administration such as oral or parenteral administration. Administration in the method of the invention is preferably oral or parenteral administration.
In general, it has proved advantageous to administer intravenously amounts of from 0.01 mg to 10 mg/kg, preferably 0.05 to 5 mg/kg, of body weight per day and to administer orally 0.05 to 20 mg/kg, preferably 0.5 mg to 5 mg/kg of body weight per day, to achieve effective results. Nevertheless, it can at times be necessary to deviate from those dosage rates, and in particular to do so as a function of the nature and body weight of the human or animal subject to be treated, the individual reaction of this subject to the treatment, type of formulation in which the active ingredient is administered, the mode in which the administration is carried out and the point in the progress of the disease or interval at which it is to be administered. Thus, it may in some case suffice to use less than the above-mentioned minimum dosage rate, whilst other cases the upper limit mentioned must be exceeded to achieve the desired results. Where larger amounts are administered, it may be advisable to divide these into several individual administrations over the course of the day.
The invention will now be described with reference to the following non-limiting examples.
Example 1: Synthesis of 3'-deoxythymidin-2'-ene (3'-deoxy-2',3'-didehydrothymidine)
A solution of the cyclic ether 3 (see the reaction scheme described hereinabove) (8.64 g, 38.4 mmol) in 240 ml of dried DMSO containing 8.70 g (76.4 mmol) of potassium t-butoxide was stirred at room temperature for two hours. The reaction mixture was neutralized to a pH of approximately 7 with ethanolic acetic acid, and the solution was then evaporated to dryness at approximately 50 °C under reduced pressure. The residue was triturated with several portions of hot acetone. The insoluble materials were removed by filtration, and the filtrate was evaporated to dryness. The residue was eluted through a silica gel column (CHCl3-EtOH, 2:1) to yield 6.5 g (76%) of product: mp 158-160°C; NMR (Me2SO-d6) xxx 1.82 (s, 3H, 5-CH3), 3.53 (m, 2H, 5'-H), 4.80 (m, 1H, 4'-H), 4.96 (t, 1H, 5'-OH, D2O exchangeable), 5.90 (m, 1H, 3'-H, vinyl), 6.40 (m, 1H, 2'-H, vinyl), 6.82 (m, 1H, 1'-H), 7.67 (s, 1H, 6-H).
Example 2: Biological Assay Procedure for Antiviral Activity Against the Human Immunodeficiency Virus (HIV; HTLV-III/LAV)
Three day-old mitogen stimulated human peripheral blood mononuclear (PBM) cells (106 per ml) were infected with HIV (strain LAV) in the presence and absence of various concentrations of 3-deoxythymidin-2'-ene, 1, 10, 100 μM. Five days after infection, the virus in the supernatant was pelleted and, after disruption, the reverse transcriptase activity was determined.
The methods used for culturing the PBM cells, harvesting the virus and determination of reverse transcriptase activity were those described by J. S. McDougal, S. P. Cort, M. S. Kennedy, C. D. Cabridilla, P. M. Feorino, D. P. Francis, D. Hicks, V. S. Kalyanaramen and L. S. Martin, J. Immun. Meth., 76, 171, (1985). The virus was added to the cultures at the same time as the drug.
The data obtained indicated that essentially complete inhibition of the replication of the "AIDS" virus was obtained (>98% inhibition) at all three concentrations.
Example 3: Biological Assay Procedure for Antiviral Activity Against Moloney Murine Leukemia Virus (M-MuLV) by XC-Assay
The XC assay system is an indirect method for quantitation of murine-leukemia virus (MuLV) originally described by V. Klement, W. P. Rowe, J. W. Hartley and W. E. Pugh, Proc. Natl. Acad. Sci., 63, 753, (1969) and modified by W. P. Rowe, W. E. Pugh and J. W. Hartley, Virology, 42, 1136, (1970). This test is based on the development of syncytial changes in the XC cell line when it is co-cultivated with mouse fibroblast cells (SC-1 cells) productively infected with MuLV. The XC cell line was derived from a rat tumor induced by the prague strain of Rouse Sarcoma Virus (RSV) (J. Svoboda, P. Chyle, D. Simkovic and J. Hilgert, Folia Biol., 9, 77, 1963)). This cell line contains the RSV genome, but does not produce infectious virus in the absence of a helper virus.
10E6 SC-1 cells were seeded in Earls Minimum Essential Medium (EMEM)-10% Fetal Bovine Serum (FBS), onto 60 mm petri dishes. The following day, the cells were inoculated with 0.5 ml of a virus dilution containing 25 25 μg/ml of DEAE-dextran. The dishes were maintained for 1 hour at 37° C in a humidified 5% CO2 incubator. The virus inoculum was then removed and replaced with 5 ml of medium containing appropriate concentrations of the test compound (two dishes/concentration). Medium containing 10% FBS was added to the virus control dishes. The medium (with or without the test compound) was changed at 48 hours.
Five days after virus inoculation, the culture fluid was decanted, and the cells were irradiated with a "General Electric" germicidal bulb for 30 seconds (1500-1800 ergs UV-light). Cultures were immediately overlaid with 10E6 SC cells in 5 ml of EMEM-10% FBS/dish. The medium was changed at 2-day intervals. Four days after XC cells addition, cultures were simultaneously fixed and stained with GEIMSA™ for 10 to 15 minutes.
Plaques were counted using an inverted microscopy as holes in the cell sheet containing syncytial cells, or as focal masses of multinucleated giant cells. The antiviral activity was highly significant and had an ED50 of 2.5 μM.
Calculation of % Inhibition/Concentration (% Inh./conc.):
ED50: Accumulative % Inhibition using the Reed-Muench Method Claims
1. A pharmaceutical composition for treating warm blooded animals infected with a retrovirus, comprising as an active ingredient an anti-retroviral effective amount of 3'-deoxythymidin-2'-ene, either alone or in admixture with usual additives such as a solid, liquid or liquefied gaseous diluents.
2. A composition according to claim 1, wherein the retrovirus is Moloney murine leukemia virus.
3. A composition according to claim 1, wherein the retrovirus is HTLV Ill/LAV.
4. A composition according to anyone of claims 1 to 3, containing 0.5 to 90 % of said active ingredient.
5. A composition according to anyone of claims 1 to 4, in the form of a sterile physiologically isotonic aqueous solution.
6. A composition according to claim 5 containing 0.5 to 90 % of said active ingredient.
7. A composition according to anyone of claims 1 to 6 in the form of a medicament in dosage unit form, such as in the form of a tablet, pill, dragee, capsule, caplet, ampoule or suppository.
8. The use of 3'-deoxythymidin-2'-ene or of a pharmaceutical composition according to anyone of claims 1 to 7 for the preparation of a medicament for the treatment of warm blooded animals infected with a retrovirus.
1. Composition pharmaceutique pour le traitement d'animaux à sang chaud infectés par un rétrovirus, comprenant, comme ingrédient actif, une quantité anti-rétrovirale efficace de désoxy-3' thymidinène-2', soit seul, soit en mélange avec des additifs usuels, tels que des diluants solides, liquides ou sous forme de gaz liquéfiés.
2. Composition selon la revendication 1, dans laquelle le rétrovirus est le virus de la leucémie murine de Moloney.
3. Composition selon la revendication 1, dans laquelle le rétrovirus est HTLV Ill/LAV.
4. Composition selon l'une quelconque des revendications 1 à 3, contenant 0,5 à 90% dudit ingrédient actif.
5. Composition selon l'une quelconque des revendications 1 à 4, sous la forme d'une solution aqueuse physiologiquement isotonique, stérile.
6. Composition selon la revendication 5, contenant 0,5 à 90% dudit ingrédient actif.
7. Composition selon l'une quelconque des revendications 1 à 6, sous la forme d'un médicament se présentant sous la forme d'unités de dosage, telles que sous la forme de pastilles, pilules, dragées, capsules, gélules, ampoules ou suppositoires.
8. Utilisation du désoxy-3' thymidinène-2' ou d'une composition pharmaceutique telle que définie à l'une quelconque des revendications 1 à 7, pour la préparation d'un médicament pour le traitement d'animaux à sang chaud infectés par un rétrovirus.
1. Pharmazeutische Zubereitung zur Behandlung von Warmblütlern, die mit einem Retrovirus infiziert sind, enthaltend als aktiven Bestandteil eine anti-retroviral wirksame Menge von 3'-Deoxythymidin-2'-en, entweder allein oder in Gemisch mit den üblichen Zusätzen, z.B. festen, flüssigen oder verflüssigten gasförmigen Verdünnungsmitteln.
2. Zubereitung nach Anspruch 1, worin das Retrovirus Moloney-Maus-Leukämie-Virus darstellt.
3. Zubereitung nach Anspruch 1, worin das Retrovirus HTLV III/LAV darstellt.
4. Zubereitung nach einem der Ansprüche 1 bis 3, enthaltend 0,5 bis 90 % des aktiven Bestandteils.
5. Zubereitung nach einem der Ansprüche 1 bis 4 in Form einer sterilen, physiologisch isotonischen wäßrigen Lösung.
6. Zubereitung nach Anspruch 5, enthaltend 5 bis 90 % des aktiven Bestandteils.
7. Zubereitung nach einem der Ansprüche 1 bis 6 in Form einer Dosiseinheit, z.B. in Form einer Tablette, Pille, eines Dragees, einer Kapsel, Kaplette, Ampulle oder eines Suppositoriums.
8. Verwendung von 3'-Deoxythymidin-2'-en oder einer pharmazeutischen Zubereitung nach einem der Ansprüche 1 bis 7 zur Herstellung eines Medikaments für die Behandlung von Warmblütlern, die mit einem Retrovirus infiziert sind.